Q218—public flotation jackpot
Sign Up to like & getrecommendations! Published in 2018 at "Nature Biotechnology"
DOI: 10.1038/nbt.4249
Abstract: Sage Therapeutics Shionogi 90 Sage grants Shionogi exclusive rights in Japan, Taiwan and South Korea to SAGE-217, a next-generation GABAA positive allosteric small-molecule modulator to treat major depressive disorder Skyhawk Therapeutics Celgene 60 Skyhawk grants… read more here.
Keywords: exclusive rights; develop commercialize; q218 public; small molecule ... See more keywords
A phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz253.093
Abstract: Abstract Background CS1001 is a first full-length, fully human anti-PD-L1 mAb developed by the OMT transgenic rat platform, which mirrors natural IgG4 human antibody with expected pharmacokinetics (PK) profiles, and may potentially reduce the risk… read more here.
Keywords: cs1001; advanced solid; pts advanced; cstone pharmaceuticals ... See more keywords